• Company
  • Products
  • Medical education
  • News & events
  • Contact Sales

We can help!

Contact one of our representatives or attend our medical education courses.

  • Questions url
  • Medical book icon
  • Envelope icon
  • Company
    • About Bioceramed

    • Contact Us

    • Careers

    • Social Responsibility

    • Projects

  • Products
    • Bone Grafts

    • Platelet-Rich Plasma & Fibrin

    • Hyaluronic Acid

    • Membranes

  • Get in touch
    • Questions or feedback?

      We’d love to hear from you

  • An Hydrumedical company
Co-financed by
  • https://bioceramed.cdn.prismic.io/bioceramed/Zo2b5x5LeNNTw9rd_Portugal2020.svg
  • https://bioceramed.cdn.prismic.io/bioceramed/Zo2b5h5LeNNTw9rc_Norte2020.svg
  • https://bioceramed.cdn.prismic.io/bioceramed/Zo2b6R5LeNNTw9re_UE.svg?auto=compress,format
  • https://images.prismic.io/bioceramed/aOzQO55xUNkB14SM_Pessoas2030.png?auto=format%2Ccompress&w=132&h=40
  • https://images.prismic.io/bioceramed/aMPVYGGNHVfTPFAL_Compete2030.png?auto=format%2Ccompress&w=132&h=40
  • https://images.prismic.io/bioceramed/aOzP6p5xUNkB14SF_Portugal2030.png?auto=format%2Ccompress&w=132&h=40
  • https://images.prismic.io/bioceramed/aMPVamGNHVfTPFAM_UE.png?auto=format%2Ccompress&w=132&h=40

© 2026 Bioceramed

  • Terms and Conditions
  •   |  Privacy policy
  •   |  Cookies policy
Medical Education
Twelve Months of Clinical Follow-Up with TriOSS®
Aug, 07 - 20261 min. read

TriOSS® in Dental Bone Regeneration: Twelve-Month Clinical Results

Resumo de página, para levar ao download. Cerca de 150 palavras.

TriOSS® in Dental Bone Regeneration: Twelve-Month Clinical Results

TriOSS® is a synthetic, resorbable beta-tricalcium phosphate bone substitute manufactured by Bioceramed in Portugal. This clinical evidence summary presents the twelve-month interim results of a prospective, single-centre, single-arm observational study conducted at Egas Moniz School of Health and Science under Dr. João Botelho.

Eighty adult patients undergoing dental reconstructive surgery were enrolled, predominantly for alveolar ridge preservation. Bone consolidation was assessed radiographically, alongside adverse events, device deficiencies, clinician usability, and patient-reported oral health measured with the OHIP-14.

Bone consolidation was confirmed in every patient evaluated at both the six-month and twelve-month visits. No adverse events were recorded at any assessment point across the first twelve months. Oral health-related quality of life improved significantly and the improvement was sustained at one year.

The study is ongoing. The full document sets out the results in detail, together with follow-up rates and all study limitations.

  • Download

    Access the Full Document